Sanofi to axe 466 R&D positions in Germany and France

pharmafile | June 21, 2019 | News story | Medical Communications, Research and Development, Sales and Marketing Sanofi, pharma 

Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs across Germany and France as part of a “voluntary departure programme”.

The French drugmaker revealed the move as it aims to downscale its development of cardiovascular drugs in favour of work in the areas of immuno-oncology, vaccines and rare disease. The firm said it would no longer pursue new development projects in the cardiovascular and diabetes space, instead focusing only on its existing research programmes.

The 466 cuts will be taken up voluntarily by willing staff members. Sanofi currently employs over 100,000 staff worldwide, with 15,000 installed in R&D functions.

Matt Fellows

Related Content

Pharmanovia acquires CNS portfolio from Sanofi

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content